Fortress Biotech Inc(FBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 0.97 | EPS (ttm) | 2.66 | Insider Own | 31.02% | Shs Outstand | 33.3M | Perf Week | -5.86% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | -139.22% | Insider Trans | - | Shs Float | 23.0M | Perf Month | -1.53% |
| Enterprise Value | -0.02B | PEG | - | EPS next Q | -0.27 | Inst Own | 22.84% | Short Float | 24.24% | Perf Quarter | -7.22% |
| Income | 0.10B | P/S | 1.25 | EPS this Y | 3742.86% | Inst Trans | 3.04% | Short Ratio | 9.58 | Perf Half Y | -20.19% |
| Sales | 0.07B | P/B | 0.52 | EPS next 5Y | - | ROA | 46.92% | Short Interest | 5.58M | Perf YTD | -29.78% |
| Book/sh | 4.93 | P/C | 0.44 | EPS past 3/5Y | 83.35% 62.98% | ROE | 107.48% | 52W High | -43.27% ($4.53) | Perf Year | -33.42% |
| Cash/sh | 5.89 | P/FCF | 0.71 | Sales past 3/5Y | -5.83% 6.77% | ROIC | 53.19% | 52W Low | 17.89% ($2.18) | Perf 3Y | -55.84% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 401.39% | Gross Margin | 58.88% | Volatility(W/M) | 2.7% 5.13% | Perf 5Y | -94.89% |
| Dividend TTM | - | EV/Sales | -0.23 | Sales Y/Y TTM | 15.46% | Oper. Margin | -42.86% | ATR (14) | 0.14 | Perf 10Y | -92.8% |
| Dividend Ex-Date | - | Quick Ratio | 3.83 | EPS Q/Q | -117.4% | Profit Margin | 150.97% | RSI (14) | 36.04 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.96 | Sales Q/Q | 14.04% | SMA20 | -7.81% ($2.79) | Beta | 1.23 | Target Price | $5 |
| Payout | - | Debt/Eq | 0.32 | Earnings | 2026/8/13 | SMA50 | -14.54% ($3.01) | Rel Volume | 0.54 | Prev Close | $2.63 |
| Employees | 78 | LT Debt/Eq | 0.28 | EPS/Sales Surpr. | 60% 2.28% | SMA200 | -14.57% ($3.01) | Avg Volume(3M) | 0.58M | Price | $2.57 |
| IPO | 2011/11/17 | Option/Short | Yes/Yes | Trades | 1430 | Volume | 315,457 | Change | -2.28% |
Company
FBIO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Fortress Biotech is a U.S. biopharmaceutical holding company that acquires, develops, and commercializes pharmaceutical and biotechnology products through multiple subsidiaries. It operates a number of subsidiaries across oncology, rare diseases, and dermatology, with a decentralized development structure in which each subsidiary independently manages its own drug pipeline and marketed products.
Over the past 1 year, on the lower side
43% below its 1-year high.
FBIO has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +3742.9% this year.
Tap to view numbers
The stock looks undervalued
Trading at 1.0 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -55.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 22.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%
VXF 0.00%
BSVO -It ranks #4 in the industry
Based on market cap of $86M.
FBIO $86M PER 1.0
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is FBIO?
FBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of FBIO?
The market cap of FBIO is approximately $86M, ranking 4,653 within its sector.
What is the P/E ratio of FBIO?
FBIO has a P/E ratio of approximately 1.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for FBIO?
FBIO has recorded a 52-week high of $4.53 and a low of $2.18.
